BioMarin ends development of oral AATD liver disease candidate BMN 349

BIOMARIN PHARMACEUTICAL INC

Discontinued BMN 349, an oral therapeutic for alpha-1 antitrypsin deficiency (AATD)-associated liver disease.
Decision announced on December 19, 2025; no reason for discontinuation disclosed.
No financial impact or pipeline replacement details provided in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.